Drugs / rhIGF-1/rhIGFBP-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00351221 | — | Noonan syndrome | Insmed Incorporated | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIGF-1/rhIGFBP-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00351221 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3” NCT00351221 ↗ |